greeksoup/ stock research

Concentra Group Holdings Parent, Inc.: Q1 FY2026 earnings call

What management said about Q1 FY2026, from the documents filed with the SEC on 7 May 2026: press release. Guidance figures: 5 raised, 2 kept. The quarter’s numbers.

Key takeaways

  • Revenue and net income both rose: Revenue was $569.6 million, up 13.7%. Net income was $52.3 million, up 28.7%. Net income attributable to the Company was $50.5 million, up 29.8%. Source
  • Adjusted EBITDA margin rose: Adjusted EBITDA was $120.7 million, 21.2% of revenue, against $102.7 million, or 20.5% of revenue, a year earlier. Source
  • Visits per day rose 6.7%: Patient visits totaled 3,419,091, or 54,271 per day, against 50,863 a year earlier. Both periods had 63 business days. Source
  • Onsite clinics grew to 411: Onsite health clinics stood at 411 at March 31, against 160 a year earlier. Onsite clinic revenue was $37.2 million, against $16.6 million. Source
  • Cost of services grew 11.8%: Cost of services, excluding depreciation and amortization, was $399.1 million against $357.1 million. Revenue grew 13.7% over the same period. Source
  • Free cash flow turned positive: Free cash flow was $9.9 million, against negative $4.0 million a year earlier. Operating cash flow was $21.0 million, against $11.7 million. Source
  • Net leverage about 3.4x, covenant met: Cash was $61.7 million and total debt was $1,576.1 million. Net leverage was about 3.4x, in compliance with the credit agreement covenant. Source

“The meaningful growth in visit volumes we saw this quarter demonstrates that our clinical model and value proposition continue to lead in workers' compensation.”

Keith Newton, Chief Executive Officer of Concentra

Guidance

AreaPeriodFigureAgainst last quarter
Revenue SourceFY 2026$2.275 billion to $2.375 billionRaised from $2.25 billion to $2.35 billion
Adjusted EBITDA SourceFY 2026$460 million to $480 millionRaised from $450 million to $470 million
Net income attributable to the Company SourceFY 2026$184 million to $199 millionRaised from $176 million to $191 million
Net leverage ratio SourceFY 2026below 3.0xKept
Free Cash Flow SourceFY 2026$215 million to $235 millionRaised from $200 million to $225 million
Net cash provided by operating activities SourceFY 2026$295 million to $305 millionRaised from $280 million to $295 million
Capital expenditures SourceFY 2026$70 million to $80 millionKept

What changed from last quarter

  • Guidance raised: Full-year revenue, Adjusted EBITDA, net income attributable to the Company and Free Cash Flow ranges raised from the prior release. Source
  • Guidance kept: Capital expenditure range of $70 million to $80 million unchanged from the prior release. Source
  • New: Three occupational health centers acquired in the quarter; none were acquired in the fourth quarter of 2025. Source

Results and growth drivers

  • Revenue and net income both rose: Revenue was $569.6 million, up 13.7%. Net income was $52.3 million, up 28.7%. Net income attributable to the Company was $50.5 million, up 29.8%. Source
  • EPS and adjusted EPS higher: Basic and diluted EPS was $0.39 against $0.30. Adjusted EPS was $0.40 against $0.33, with adjusted net income attributable to the Company of $51.5 million. Source
  • Adjusted EBITDA margin rose: Adjusted EBITDA was $120.7 million, 21.2% of revenue, against $102.7 million, or 20.5% of revenue, a year earlier. Source

Patient volumes and pricing

  • Visits per day rose 6.7%: Patient visits totaled 3,419,091, or 54,271 per day, against 50,863 a year earlier. Both periods had 63 business days. Source
  • Revenue per visit rose 3.1%: Revenue per visit was $151.47 against $146.94. Workers' compensation revenue per visit was $213.27, up 2.0%. Employer services was $96.91, up 2.7%. Source
  • Workers' compensation visits led growth: Workers' compensation visits per day rose 9.6% to 25,132. Employer services visits per day rose 4.8% to 28,231. Consumer health visits per day fell 9.4%. Source

“Our Q1 results demonstrate the inherent strength of our operating model, with broad-based growth across our business supporting our decision to raise our full-year guidance.”

Matt DiCanio, Concentra’s President and Chief Financial Officer

Facilities and onsite clinics

  • Onsite clinics grew to 411: Onsite health clinics stood at 411 at March 31, against 160 a year earlier. Onsite clinic revenue was $37.2 million, against $16.6 million. Source
  • Three centers acquired, one de novo: The occupational health center count rose from 628 to 632. Three centers were acquired and one de novo opened. None closed. Source
  • Center revenue split by payer type: Occupational health center revenue was $519.9 million, against $472.9 million. Workers' compensation was $337.7 million and employer services was $172.4 million. Source

Costs and margins

  • Cost of services grew 11.8%: Cost of services, excluding depreciation and amortization, was $399.1 million against $357.1 million. Revenue grew 13.7% over the same period. Source
  • G&A rose 18.3%: General and administrative expense was $55.3 million against $46.7 million. Transition services fees were $1.6 million, against $3.7 million. Source
  • Separation and acquisition costs lower: Separation transaction costs were $1.1 million against $0.3 million. Nova and Pivot Onsite acquisition costs were $0.2 million against $3.1 million. Source
  • Depreciation and amortization up 18.2%: Depreciation and amortization was $19.6 million, up 18.2%. Stock compensation expense was $4.1 million, against $2.3 million a year earlier. Source

Cash flow and leverage

  • Free cash flow turned positive: Free cash flow was $9.9 million, against negative $4.0 million a year earlier. Operating cash flow was $21.0 million, against $11.7 million. Source
  • Operating cash flow rose with earnings: Management attributed the rise in operating cash flow to higher earnings in 2026. Net cash provided by operating activities was $21.0 million. Source
  • Capital spending fell 29.5%: Capital expenditures were $11.1 million, down 29.5%. Business combinations used $3.8 million net of cash acquired, against $279.0 million a year earlier. Source
  • Net leverage about 3.4x, covenant met: Cash was $61.7 million and total debt was $1,576.1 million. Net leverage was about 3.4x, in compliance with the credit agreement covenant. Source

Capital returns to shareholders

  • Shares repurchased for $15.0 million: About 0.7 million shares were repurchased for $15.0 million. The prior-year quarter had no share repurchases. Source
  • Quarterly dividend declared at $0.0625: The board declared a $0.0625 per share cash dividend on May 5, 2026. Dividends paid to common stockholders were $8.0 million in the quarter. Source

Strategy and independence

  • Platform optimization as independent company: Management said that, as an independent company, it is optimizing its operational platform and infrastructure to drive sustained excellence. Source
  • Focus on de novo pipeline: Management said it is focused on disciplined execution of its de novo pipeline, with one de novo center opened in the quarter. Source

Coming up, as management said on 7 May 2026

  • Dividend payment date: The $0.0625 dividend is payable on or about June 9, 2026, to holders of record at the close of business on May 19, 2026. Source

Figures management reported

FigureReported
Patient visits per day Source54,271, up 6.7% from 50,863
Workers' compensation visits per day Source25,132, up 9.6% from 22,935

Earlier plans management reported on

  • On track: Management said it is on track to complete its transition from Select Medical in the coming months. Source

Other quarters

Summarised with AI from the documents the company filed with the SEC. Every point is checked against the filing before it is shown: management’s own words word for word, figures against the line or table row they come from. A point that fails the check is left out. Source opens the filing at that line.